The Potential Benefits of Akkermansia muciniphila as a Next-Generation Probiotic in the Maintenance of Overall Liver Health

Background and study aim: The gut-liver axis and gut microbiota, with a particular focus on Akkermansia muciniphila, a next-generation probiotic, have been identified as significant factors in preventing the development and progression of liver diseases. This review aims to discuss the potential therapeutic role of A. muciniphila in maintaining liver health, focusing on the latest findings from preclinical and clinical studies.

Methods: To achieve the review’s purpose, the most common keywords were searched in three online databases (PubMed, bioRxiv, and Google Scholar).

Results: The search approach identified 49 references. Studies have shown that the gut microbiota, including A. muciniphila, has the potential to be a therapeutic target for many hepatic disorders. Several studies have demonstrated A. muciniphila’s beneficial effects on improving metabolic parameters, including insulin resistance, blood cholesterol levels, and overall liver function.

Conclusions: Further research is necessary to determine the optimal dosage, duration, and administration route of A. muciniphila for managing hepatic disorders. While there are promising findings, a more thorough understanding of the underlying mechanisms and the development of effective therapeutic strategies are necessary for successful treatment of liver diseases.

Keywords: Akkermansia muciniphila, liver diseases, NAFLD, gut microbiota, probiotic.